Account
Inquiry
Tirzepatide (CAS 2023788-19-2) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research applications. This white powder compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 agonists.
The molecular structure of Tirzepatide features a PEG-modified lysine side chain that enhances water solubility while maintaining biological activity. Clinical studies indicate significant weight reduction potential, with trial participants showing average weight loss of 15-20% over 72 weeks at therapeutic doses.
As a research chemical, Tirzepatide compound offers scientists an important tool for studying metabolic disorders. The dual agonist mechanism provides unique opportunities to investigate GIP and GLP-1 receptor interactions and their effects on glucose homeostasis.
Our pharmaceutical grade Tirzepatide is supplied in convenient 10mg vials (10vials/box) to meet various research requirements. The compound undergoes rigorous quality control to ensure 99.9% purity and consistent batch-to-batch performance.
Important Note: This product is intended for research purposes only. Not for human consumption. Researchers should follow proper peptide storage guidelines including protection from light, moisture, and repeated freeze-thaw cycles.
